Search hospitals > Maryland > Bethesda
National Institutes of Health Clinical Center, 9000 Rockville Pike
Claim this profileBethesda, Maryland 20817
Global Leader in Cancer
Global Leader in Healthy Subjects
Conducts research for Lymphoma
Conducts research for Pancreatic Cancer
Conducts research for Breast Cancer
3382 reported clinical trials
27 medical researchers
Summary
National Institutes of Health Clinical Center, 9000 Rockville Pike is a medical facility located in Bethesda, Maryland. This center is recognized for care of Cancer, Healthy Subjects, Lymphoma, Pancreatic Cancer, Breast Cancer and other specialties. National Institutes of Health Clinical Center, 9000 Rockville Pike is involved with conducting 3,382 clinical trials across 2,729 conditions. There are 27 research doctors associated with this hospital, such as A P. Chen, Nirali N. Shah, John Glod, MD, and Naoko Takebe.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Healthy Subjects
Global LeaderStage I
Stage II
TSPO
Top PIs
A P. ChenNational Institutes of Health Clinical Center3 years of reported clinical research
Expert in Cancer
Expert in Pancreatic Cancer
25 reported clinical trials
68 drugs studied
Nirali N. ShahNational Institutes of Health, Clinical Center8 years of reported clinical research
Studies Acute Myeloid Leukemia
Studies Leukemia
12 reported clinical trials
16 drugs studied
John Glod, MDNational Cancer Institute Pediatric Oncology Branch9 years of reported clinical research
Studies Brain Tumor
Studies Low Grade Glioma
10 reported clinical trials
13 drugs studied
Naoko TakebeNational Institutes of Health Clinical Center8 years of reported clinical research
Studies Pancreatic Cancer
Studies Cancer
7 reported clinical trials
13 drugs studied
Clinical Trials running at National Institutes of Health Clinical Center, 9000 Rockville Pike
Cancer
Depression
Colorectal Cancer
Ovarian Cancer
Pancreatic Cancer
Healthy Subjects
Obesity
Multiple Myeloma
Lyme Disease
Cardiovascular Disease
Peposertib + Tuvusertib
for Advanced Cancer
This phase I trial tests the safety, side effects and best dose of peposertib (M3814) in combination with tuvusertib (M1774) in treating patients with solid tumors that have spread to other places in the body (advanced). Peposertib and tuvusertib stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recruiting1 award Phase 1
Pomalidomide + Nivolumab
for Viral Associated Cancers
Background: Less toxic and more effective treatments are needed for cancers caused by viruses. These cancers include Hodgkin and non-Hodgkin lymphoma, hepatocellular carcinoma, head and neck cancer, nasopharyngeal carcinoma, gastric cancer, anal cancer, cervical cancer, vaginal cancer, vulvar cancer, penile cancer, Merkel cell carcinoma, Kaposi sarcoma, and leiomyosarcoma. Researchers want to see if a combination of drugs can help. Objective: To find a safe dose of pomalidomide plus nivolumab in people with cancers caused by viruses. Eligibility: Adults ages 18 or older who have cancers caused by Epstein Barr virus (EBV), human herpes virus 8/Kaposi sarcoma herpesvirus (HHV8/KSHV), human papilloma virus (HPV), hepatitis B or C virus (HBV/HCV), and Merkel cell polyomavirus (MCPyV) that have not responded to previous treatments or have relapsed, or in adults who do not want to have surgery because of disfigurement or other risks. Adults who have HIV with any CD4 T cell count are eligible. Design: Participants will be screened with blood and urine tests, scans, and heart tests. They will have a physical exam. Their ability to perform normal daily activities will be assessed. They may have a tumor biopsy. Treatment will be given in 28-day cycles. Participants will take pomalidomide as a tablet by mouth for 21 days of each cycle, for up to 24 cycles. They will get nivolumab by intravenous infusion once each cycle. They will take an aspirin each day until 30 days after their last dose of the study drugs. Participants will keep a pill diary. They will bring it to their study visit at the end of each cycle. At these visits, some screening tests will be repeated. Participants with Kaposi sarcoma will have pictures taken of their lesions. Participants will give blood and saliva samples for research. They may have optional anal and/or cervical swabs. They may have optional biopsies. Participants will have a follow-up visit 30 days after they stop taking the study drugs, then every month for 100 days. Some screening tests will be repeated. Then they may by contacted by phone every 3 months for 9 months, and then every 6 months thereafter....
Recruiting1 award Phase 118 criteria
Enasidenib
for Sinonasal and Skull Base Cancer
Background: Cancers of the nasal cavity or skull base are rare. They often are not diagnosed until they are at an advanced stage, and they often spread to other parts of the body. These cancers may have mutations in a gene called IDH2. Researchers want to find out if a drug (enasidenib) that targets the IDH2 mutation can help people with these cancers. Objective: To test enasidenib in people with cancers of the nasal cavity or skull base. Eligibility: People aged 18 years and older with rare cancers of the nasal cavity or the base of the skull. Their cancer must have an IDH2 gene mutation, and it must have recurred locally or spread to other parts of the body. These cancers can include sinonasal undifferentiated carcinoma; olfactory neuroblastoma; sinonasal large-cell neuroendocrine carcinoma; poorly differentiated sinonasal adenocarcinoma; or chondrosarcoma. Design: Participants will be screened. They will have a physical exam with blood and urine tests and tests of their heart function. They will have imaging scans of their brain, skull base, neck, chest, abdomen, and pelvis. A sample of tumor tissue will be collected. Enasidenib is a tablet taken by mouth with a glass of water. Participants will take the drug once a day, every day, in 28-day cycles. They will not have resting periods between cycles. Participants will visit the clinic on the first day of each cycle to receive the tablets they will need to take at home until the beginning of the next cycle. They will keep a diary to record the time of each dose they take. Participants may remain in the study as long as the drug is helping them....
Recruiting1 award Phase 2
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at National Institutes of Health Clinical Center, 9000 Rockville Pike?
National Institutes of Health Clinical Center, 9000 Rockville Pike is a medical facility located in Bethesda, Maryland. This center is recognized for care of Cancer, Healthy Subjects, Lymphoma, Pancreatic Cancer, Breast Cancer and other specialties. National Institutes of Health Clinical Center, 9000 Rockville Pike is involved with conducting 3,382 clinical trials across 2,729 conditions. There are 27 research doctors associated with this hospital, such as A P. Chen, Nirali N. Shah, John Glod, MD, and Naoko Takebe.
Where is National Institutes of Health Clinical Center, 9000 Rockville Pike located?
To reach the National Institutes of Health Clinical Center in Bethesda, Maryland:
- From I-495 (Capital Beltway), take Exit 34 and head south on Route 355 (Wisconsin Ave./Rockville Pike).
- Turn right onto West Cedar Lane, then left into the patient entrance on West Drive, open daily from 6 am to 10 pm.
- Outside these hours, use the Commercial Vehicle Inspection Facility on Rockville Pike (Route 355) between North Drive and Wilson Drive, open daily from 10 pm to 6 am. Show a government-issued photo ID and follow signs to the "Clinical Center".
Who should I call to ask about financial aid or insurance network?
**National Institutes of Health (NIH) Clinical Center Contact Information:**
- **General Inquiries:** (301) 496-4000
- **Study Assistance:** 1-800-411-1222 or 1-866-411-1010 (TTY)
- **Cashier's Office:** 301-496-2654
- **Patient Representative:** 301-496-2626
- **Children's School:** 301-496-2077
- **Social Work:** 301-496-2381 (Local), 1-888-676-5668 (Toll-Free)
- **Developmental Therapeutics Clinic:** 1-800-4-Cancer (1-800-422-6237)
- **Patient Recruitment and Liaison Office:** 1-800-411-1222
What insurance does National Institutes of Health Clinical Center, 9000 Rockville Pike accept?
The National Institutes of Health Clinical Center accepts the Federal Employees Health Benefits (FEHB) program. The Foundation for the Advanced Education in the Sciences (FAES) partners with Trustmark and MetLife to provide medical/prescription, dental, and vision insurance plans for NIH Fellows and their families.
What awards or recognition has National Institutes of Health Clinical Center, 9000 Rockville Pike received?
The National Institutes of Health Clinical Center, located in Bethesda, Maryland, is a leading research hospital that has been awarded the 2011 Lasker~Bloomberg Public Service Award for its innovative therapy and transformation of scientific advances into practical applications. It receives significant funding for research and care, primarily through annual discretionary appropriations. Over 84% of the NIH budget supports extramural research, funding grants, contracts, and awards to universities and other research institutions.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.